Literature DB >> 31515707

The Association of Major Depressive Disorder with Activation of NLRP3 Inflammasome, Lipid Peroxidation, and Total Antioxidant Capacity.

Abdolghader Taene1, Ghazaleh Khalili-Tanha2, Aliakbar Esmaeili3, Leila Mobasheri1, Omid Kooshkaki1, Somaieh Jafari4, Alireza Shokouhifar4, Gholamreza Anani Sarab5.   

Abstract

Increasing number of studies indicates that chronic inflammation and oxidative stress play an essential role in pathophysiology and some symptoms of major depressive disorder (MDD). In the present study, the inflammasome activity and oxidative stress status in untreated and antidepressant-treated MDD patients were compared to the healthy group. Blood samples were taken from 20 MDD patients receiving treatment, 20 first-episode MDD patients not receiving treatment, and 20 healthy controls. The expression level of NLRP3 and caspase-1 was measured by real-time PCR and the serum TAC and MDA were examined in the patients and the control groups. The results showed that the mRNA level of NLRP3 and caspase-1 genes was significantly elevated in MDD groups compared with that in the healthy volunteers (P < 0.005). The expression level of NLRP3 and caspase-1 has slightly decreased in the treated group compared with that in the untreated one, but it was not a meaningful decrease. Moreover, the serum MDA was significantly higher and TAC statistically was lower in untreated MDD patients compared with those in the healthy control group (P = 0.001, P = 0.001). It can be concluded that NLRP3 inflammasome is upregulated in MDD patients. Statistically significant reduction in the level of TAC along with increased lipid peroxidation was detectable in MDD patient's plasma. In contrast, there was no significant difference between the treated and non-treated groups in terms of oxidative stress (P = 0.6, P = 0.1). Our results suggested that inflammasome signaling pathway is a therapeutic potential for MDD.

Entities:  

Keywords:  Lipid peroxidation (LPO); Major depressive disorder; NLRP3 inflammasome; Total antioxidant activity

Mesh:

Substances:

Year:  2019        PMID: 31515707     DOI: 10.1007/s12031-019-01401-0

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  26 in total

Review 1.  Review: the role of inflammation in depression.

Authors:  Amisha Patel
Journal:  Psychiatr Danub       Date:  2013-09       Impact factor: 1.063

2.  Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy.

Authors:  Roberto Leo; Giorgio Di Lorenzo; Manfredi Tesauro; Cinzia Razzini; Giovanni B Forleo; Gaetano Chiricolo; Clarissa Cola; Marco Zanasi; Alfonso Troisi; Alberto Siracusano; Renato Lauro; Francesco Romeo
Journal:  J Clin Psychiatry       Date:  2006-11       Impact factor: 4.384

Review 3.  The role of inflammation in depression: from evolutionary imperative to modern treatment target.

Authors:  Andrew H Miller; Charles L Raison
Journal:  Nat Rev Immunol       Date:  2016-01       Impact factor: 53.106

4.  Antidepressants induce autophagy dependent-NLRP3-inflammasome inhibition in Major depressive disorder.

Authors:  Elísabet Alcocer-Gómez; Nieves Casas-Barquero; Matthew R Williams; Samuel L Romero-Guillena; Diego Cañadas-Lozano; Pedro Bullón; José Antonio Sánchez-Alcazar; José M Navarro-Pando; Mario D Cordero
Journal:  Pharmacol Res       Date:  2017-05-02       Impact factor: 7.658

5.  NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder.

Authors:  Elísabet Alcocer-Gómez; Manuel de Miguel; Nieves Casas-Barquero; Jéssica Núñez-Vasco; José Antonio Sánchez-Alcazar; Ana Fernández-Rodríguez; Mario D Cordero
Journal:  Brain Behav Immun       Date:  2014-02       Impact factor: 7.217

Review 6.  The inflammasome: pathways linking psychological stress, depression, and systemic illnesses.

Authors:  Masaaki Iwata; Kristie T Ota; Ronald S Duman
Journal:  Brain Behav Immun       Date:  2012-12-20       Impact factor: 7.217

7.  Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B12, and serotonin levels in lymphocytes.

Authors:  Gustavo Resler; Renée Lavie; Julio Campos; Salvador Mata; Mary Urbina; Alberto García; Rafael Apitz; Lucimey Lima
Journal:  Neuroimmunomodulation       Date:  2008-08-21       Impact factor: 2.492

8.  Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia.

Authors:  Maurício Kunz; Clarissa Severino Gama; Ana Cristina Andreazza; Mirian Salvador; Keila Mendes Ceresér; Fabiano Alves Gomes; Paulo Silva Belmonte-de-Abreu; Michael Berk; Flavio Kapczinski
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-07-06       Impact factor: 5.067

9.  Decreased expressions of Toll-like receptor 9 and its signaling molecules in chronic hepatitis B virus-infected patients.

Authors:  Seyyed Mohammad Ali Sajadi; Vahid Mirzaei; Gholamhossein Hassanshahi; Hossein Khorramdelazad; Hassan Yousefi Daredor; Seyyed Mohammad Hossein Hosseini; Mojgan Moogooi; Ali Ravary; Mohammad Kazemi Arababadi; Derek Kennedy
Journal:  Arch Pathol Lab Med       Date:  2013-11       Impact factor: 5.534

10.  Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors.

Authors:  Suchet D Khanzode; Ganesh N Dakhale; Shruti S Khanzode; Anand Saoji; R Palasodkar
Journal:  Redox Rep       Date:  2003       Impact factor: 4.412

View more
  5 in total

1.  Augmented T-cell mitochondrial reactive oxygen species in adults with major depressive disorder.

Authors:  Ann-Katrin Grotle; Ashley M Darling; Erika F Saunders; Paul J Fadel; Daniel W Trott; Jody L Greaney
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-02-18       Impact factor: 4.733

2.  "Leaky Gut" as a Keystone of the Connection between Depression and Obstructive Sleep Apnea Syndrome? A Rationale and Study Design.

Authors:  Oliwia Gawlik-Kotelnicka; Aleksandra Margulska; Agata Gabryelska; Marcin Sochal; Piotr Białasiewicz; Dominik Strzelecki
Journal:  Metabolites       Date:  2022-02-06

3.  Association of DNA Methylation of the NLRP3 Gene with Changes in Cortical Thickness in Major Depressive Disorder.

Authors:  Kyu-Man Han; Kwan Woo Choi; Aram Kim; Wooyoung Kang; Youbin Kang; Woo-Suk Tae; Mi-Ryung Han; Byung-Joo Ham
Journal:  Int J Mol Sci       Date:  2022-05-21       Impact factor: 6.208

4.  Characterizing the NLRP3 Inflammasome in Mood Disorders: Overview, Technical Development, and Measures of Peripheral Activation in Adolescent Patients.

Authors:  Xinyang Zhou; Shehan M Fernando; Alexander Y Pan; Rebecca Laposa; Kathryn R Cullen; Bonnie Klimes-Dougan; Ana C Andreazza
Journal:  Int J Mol Sci       Date:  2021-11-19       Impact factor: 5.923

Review 5.  Nuclear receptors modulate inflammasomes in the pathophysiology and treatment of major depressive disorder.

Authors:  Han Wang; Wei-Jing Kan; Yuan Feng; Lei Feng; Yang Yang; Pei Chen; Jing-Jie Xu; Tian-Mei Si; Ling Zhang; Gang Wang; Jing Du
Journal:  World J Psychiatry       Date:  2021-12-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.